- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01538563
Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer
June 22, 2017 updated by: Onconova Therapeutics, Inc.
Phase I Dose Escalation Study of ON 01910.Na by 24 Hour Continuous Infusion Per Week in Patients With Advanced Cancer
The primary purpose of this study is to determine the highest dose of ON 01910.Na that can be safely given as an intravenous infusion over 24 hours once a week in a 3-week cycle to patients with advanced solid tumors.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, dose-escalating Phase I study of ON 01910.Na in patients with advanced cancers, who have satisfied the inclusion/exclusion criteria enumerated in this protocol.
Patients will receive ON 01910.Na intravenously by 24 hour continuous infusion once every week (3 weeks per cycle), until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent.
Safety monitoring will be done for at least 3 weeks before escalation to the next dose level.
As of Amendment 7, up to 6 patients with gynecological malignancies will be enrolled at the 2400 mg/m2 dose level to determine the appropriateness of this dose as the Recommended Phase Two Dose (RPTD).
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
The Bronx, New York, United States, 10461
- Albert Einstein Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must have histologically confirmed solid tumor (leukemias and lymphomas excluded) malignancy that is incurable and for which standard (FDA approved or established standard clinical practice), curative, or palliative measures do not exist or are no longer effective.
- Patients with disease amenable to sequential biopsies will be requested to undergo two tumor biopsies and two normal skin biopsies, but patients may decline and still be eligible for enrollment during this escalation stage.
- At least 3 weeks since the last dose of other potentially myelosuppressive treatment (at least 6 weeks since last dose of nitrosoureas or mitomycin C) and recovery from manifestations of reversible drug toxicity (alopecia, stable residual neuropathy, and residual hand and foot syndrome are excluded). Patients with prior doxorubicin chemotherapy must have total cumulative dose of no more than 450 mg/m2.
- Patients with prior radiotherapy are eligible provided a minimum of 4 weeks have passed and the maximal area of hematopoietic active bone marrow treated was less than 25%.
- ECOG performance status ≤2.
- Patients must have nearly normal organ and marrow function as defined below:
- Hgb > 9 gm/dl (must not require transfusional support but erythropoietin therapy is permitted)
- WBC > 4,000 per microliter
- Absolute neutrophil count > 1,500 per microliter
- Platelets ≥ 100,000 per microliter
- Total bilirubin within 1.5 times institutional upper normal limit
- AST(SGOT)/ALT(SGPT) ≤ 2.5 x institutional upper normal limit. (If liver function abnormalities are due to metastatic disease, patients are eligible provided the transaminases are < 5 times institutional upper normal limit. Patients with primary liver disease with these parameters will be ineligible.)
- Serum creatinine within normal institutional limits or estimated creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
- Women of child-bearing potential and men must agree to use adequate contraception prior to study entry.
- Ability to understand and the willingness to sign a written informed consent document.
- All ethnic groups are eligible for this trial.
Inclusion Criteria - Dose Confirmation Phase Same inclusion criteria as in the Dose Escalation phase described above, except Patients must have an ECOG performance of 0 or 1.
Exclusion Criteria:
- Recent major surgery (within the past 14 days), chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy within 4 weeks prior to entering the study, or those who have not recovered from adverse events (except alopecia, stable residual neuropathy, and residual hand and foot syndrome) due to previously administered agents.
- Patients may not be on any other investigational agents or concurrent chemotherapy, radiotherapy, hormonal treatments, bone marrow transplantation, or immunotherapy. Patients who have previously had a Bone Marrow Transplant are excluded from this study.
- Known brain metastases, except brain metastases that have been previously removed or irradiated and currently have no clinical impact.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to ON 01910.Na.
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, bleeding, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant and nursing women are excluded.
- HIV-positive patients receiving combination anti-retroviral therapy are excluded.
- Ascites requiring active medical management including paracentesis, peripheral bilateral edema, hyponatremia (serum sodium value less than 134 Meq/L).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of dose limiting toxicities (DLTs)
Time Frame: 21 days after first administration of ON 01910.Na
|
DLTs are defined as:
|
21 days after first administration of ON 01910.Na
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Adverse Events (AEs)
Time Frame: 30 days after last infusion of study drug
|
All AEs (except Grade 1 and 2 laboratories abnormalities that do not require an intervention) are recorded in Case Report Forms and source documentation.
|
30 days after last infusion of study drug
|
Severity of Adverse Events (AEs)
Time Frame: 30 days after last infusion of study drug
|
Severity of AEs are determined according to Common Terminology Criteria for Adverse Events (Version 3.0)
|
30 days after last infusion of study drug
|
Relationship of Adverse Events (AEs) to Study Treatment
Time Frame: 30 days after last infusion of study drug
|
Relationship assessed as Not related, Unlikely, Possibly, Probably, or, Definitely according to Guidance in Appendix II of Protocol.
|
30 days after last infusion of study drug
|
Concentration of ON 01910.Na in plasma versus time
Time Frame: Up to 48 hours after infusion of study drug during Week 1 in Cycles 1 and 2
|
Blood samples will be collected at following time points: Pre-dose; 1 h after start of infusion; 3 h; 6 h; 12 h; 18 h; 24 h; 10 min after end of infusion; 20 min; 30 min; 1 h; 2 h; 4 h; 8 h; 24 h; and, 48 h.
Plasma will be prepared from these samples.
Concentration of ON 01910.Na will be determined by validated method.
|
Up to 48 hours after infusion of study drug during Week 1 in Cycles 1 and 2
|
Change in size of target lesions recorded at baseline
Time Frame: 30 days after last infusion of study drug
|
The same method of assessment for each identified and recorded lesion will be used at baseline and each follow-up.
|
30 days after last infusion of study drug
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sridhar Mani, MD, Albert Einstein College Of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Garcia-Manero G, Fenaux P. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood Dec 2016, 128 (22) 2011; ASH 2016.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2006
Primary Completion (Actual)
July 1, 2010
Study Completion (Actual)
November 1, 2011
Study Registration Dates
First Submitted
February 20, 2012
First Submitted That Met QC Criteria
February 23, 2012
First Posted (Estimate)
February 24, 2012
Study Record Updates
Last Update Posted (Actual)
June 23, 2017
Last Update Submitted That Met QC Criteria
June 22, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Onconova 04-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus NeoplasmsUnited States
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
GlaxoSmithKlineRecruitingColonic Neoplasms | Neoplasms, ColonUnited States, Finland, France, Italy, Japan, Netherlands, Norway, Spain, Taiwan, United Kingdom, Australia, Belgium, Brazil, Germany, Greece, Sweden, Turkey, Canada, Korea, Republic of, Argentina, Hungary, Estonia, Portugal, Mexico, Pa...
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong
Clinical Trials on rigosertib sodium
-
Onconova Therapeutics, Inc.CompletedMyelodysplastic Syndrome | MDS | Trisomy 8United States
-
Onconova Therapeutics, Inc.CompletedChronic Myeloid Leukemia | Acute Lymphocytic Leukemia | Acute Myelocytic Leukemia | Myeloproliferative DiseaseUnited States
-
Onconova Therapeutics, Inc.Completed
-
Onconova Therapeutics, Inc.CompletedSolid TumorUnited States
-
Onconova Therapeutics, Inc.Completed
-
Onconova Therapeutics, Inc.CompletedMyelodysplastic SyndromesUnited States, France, Germany
-
Onconova Therapeutics, Inc.CompletedHead and Neck Neoplasms | Carcinoma, Squamous CellUnited States
-
Onconova Therapeutics, Inc.CompletedNeoplasms | Cancer | Advanced Cancer | Solid TumorsUnited States
-
Prof. Johann BauerRecruiting
-
Onconova Therapeutics, Inc.CompletedMyelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Chronic Myelocytic Leukemia | Acute Lymphocytic Leukemia | Acute Myelocytic LeukemiaUnited States